Bryant Fong - Mar 7, 2022 Form 4 Insider Report for ADMA BIOLOGICS, INC. (ADMA)

Role
Director
Signature
/s/ Bryant Fong, by Brian Lenz as Attorney-in-fact
Stock symbol
ADMA
Transactions as of
Mar 7, 2022
Transactions value $
$0
Form type
4
Date filed
3/9/2022, 04:58 PM
Previous filing
Oct 26, 2021
Next filing
Mar 8, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADMA Common Stock Award $0 +26.6K +354.48% $0.00 34.1K Mar 7, 2022 Direct F1, F2
holding ADMA Common Stock 1.43M Mar 7, 2022 See Footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADMA Employee Stock Option (right to buy) Award $0 +53.2K $0.00 53.2K Mar 7, 2022 Common Stock 53.2K $1.67 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date.
F2 Includes (i) 26,586 RSUs granted on March 7, 2022 and reported on this Form 4, subject to vesting as set forth in footnote (1); and (ii) 7,500 shares of common stock owned by the reporting person.
F3 Represents shares held by Biomark Capital Fund ("Biomark Capital"). Mr. Fong is a Managing Director and General Partner at Biomark Capital and may be deemed the beneficial owner of such shares.
F4 The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.